A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to Less Than 18 Years With Invasive Aspergillosis
Latest Information Update: 20 Jan 2025
At a glance
- Drugs Posaconazole (Primary) ; Posaconazole (Primary) ; Posaconazole (Primary)
- Indications Aspergillosis
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 08 Mar 2024 This trial has been completed in Italy according to European Clinical Trials Database record.
- 14 Feb 2024 The trial has been completed in Hungary and Greece ,According to European European Clinical Trials Database.
- 08 Jan 2024 Status changed from active, no longer recruiting to completed.